Leerink Partners Maintains Buy Rating and Raises Price Target for Veradermics
Leerink Partners analyst Marc Goodman has maintained a "Buy" rating on Veradermics, Incorporated and increased the price target from $150 to $185.
Stocks · News reference
Veradermics, Incorporated reported its financial results for the third quarter ended September 30, 2026, posting a net loss of $21 million and beating analyst estimates.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Leerink Partners analyst Marc Goodman has maintained a "Buy" rating on Veradermics, Incorporated and increased the price target from $150 to $185.
Veradermics, Incorporated announced that company management will present at the Jefferies Global Healthcare Conference in London on November 19, 2026.
Filed: 2026-11-10 AccNo: 0001827635-26-000041 Size: 641 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Veradermics reports positive Phase 2/3 trial data for its oral hair loss pill, paving the way for potential FDA approval. MANE shares rise.
Veradermics, Incorporated reported topline results from its registration-directed Phase 3 clinical trial (Study '302') evaluating VDPHL01 for the treatment of pattern hair loss.